Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2013 | 03:34am CEST

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
08:21a BBA AVIATION : *jpmorgan raises bba aviation price target to 242 (204) pence - 'neutral'
08:21a TOP NEWS : Hammerson Interim Profit Lower But Confident Post-Brexit
08:21a ACACIA MINING : *jpmorgan raises acacia mining price target to 530 (490) pence - 'overweight'
08:21a ABERDEEN ASSET MANAGEMENT : says second quarter assets up on market, currency gains
08:20a Oslo børs - status companies on special observation
08:18a Double Bond Pharmaceutical AB has been granted Orphan Drug Designation status by EMA for the drug candidate Temodex.
08:17a Eyes on Fed, BOJ, Europe's bank stress test
08:15a J SAINSBURY : *bernstein cuts sainsbury(j) price target to 300 (330) pence - 'outperform'
08:15a OPTHEA : to Host Conference Call Providing Update on Phase 1 Wet AMD Clinical Trial With OPT-302
08:13aDJMalaysia's SapuraKencana Secures US$113 Million Contract in Mexico
Latest news
Advertisement
Hot News 
-0.41%Oil Prices Lower as Bearish Outlook Remains
Most Read News
07/24 FUELLING THE FIRE : new coal technologies spell disaster for climate
07/24 VERIZON COMMUNICATIONS : to announce $5 billion deal to buy Yahoo on Monday - source
Most recommended articles
02:17a Eyes on Fed, BOJ, Europe's bank stress test
02:13aDJMalaysia's SapuraKencana Secures US$113 Million Contract in Mexico
02:10a NIKKEI 225 TECHNICAL ANALYSIS : Index Stalling Below 17,000
01:56aDJPHILIPS : Profit Lifted by Health Technology Business
01:51a Ryanair says on track for record profit, but Brexit risks linger